YS247 (Neoantigen-Pulsed DC Vaccine) for Metastatic Prostate Cancer

Inclusion Criteria: * Male, age ≥18 years, with life expectancy ≥6 months. * Histologically confirmed prostate adenocarcinoma with documented metastatic disease (bone, lymph nodes, or visceral organs) by recent whole-body MRI, bone scintigraphy (ECT), or PSMA-PET/CT. * Confirmed metastatic castration-resistant prostate cancer (mCRPC) with documented disease progression after ≥1 line of novel endocrine therapy (e.g., abiraterone or enzalutamide). * ECOG performance status 0-1. * Availability of tumor tissue (fresh biopsy or archival specimen) for neoantigen screening. * Willingness to undergo long-term follow-up. * Provision of signed informed consent form by participant or legally authorized representative prior to study procedures. * Willingness to undergo prostate biopsy if required for tissue acquisition. Adequate organ function as defined by laboratory values at screening: Absolute neutrophil count (ANC) \>1.5×10⁹/L; Platelet count \>100×10⁹/L; Hemoglobin \>90 g/L; Total bilirubin, ALT, and AST within normal laboratory limits; Serum creatinine \<133 μmol/L (or \<1.5 mg/dL); INR \<1.3 (or \<3.0 if on warfarin or other anticoagulants); Albumin \>30 g/L; Left ventricular ejection fraction (LVEF) ≥45% Negative for HIV, HBV (HBV DNA ≤500 IU/mL acceptable), and HCV (HCV RNA negative); No clinically significant ECG abnormalities. Exclusion Criteria: * History of other malignancies within the past 5 years (except non-melanoma skin cancer or carcinoma in situ with documented di…